Who gets Alzheimer's drugs? Race, vulnerability and health status shape access
The first disease-modifying drugs for Alzheimer's disease offer patients the ability to slow cognitive decline by targeting amyloid plaques in the brain. But a new study suggests that not all patients have the same opportunity to receive these treatments.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
AI could help predict which HPV infections progress to cancer
United Kingdom
-
Greater contact with nature linked to a more positive relationship with food
United Kingdom
-
Protein modification partially reverses cancer-related muscle wasting in preclinical study
United Kingdom
-
Engineers use AI, Reddit to identify potential side effects of unapproved new GLP-1
United Kingdom
-
Study finds prebiotic fiber helps girls build more bone
United Kingdom
-
Antibody screening approach could speed development of immune-based cancer treatments
United Kingdom
-
Scientists restore memory-linked neuron function in Alzheimer's mice
United Kingdom
-
Mount Sinai wins NIH grant to test community-based hypertension care model in rural Ghana
United Kingdom